Exane Derivatives’s Cencora COR Stock Holding History

Exane Derivatives’s Portfolio COR Stock Details COR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$3.4K	Sell	24 -2,810	-99%	-$430K	﹤0.01%	406
2022 Q1	$438K	Sell	2,834 -455	-14%	-$64.4K	0.12%	206
2021 Q4	$437K	Sell	3,289 -1,000	-23%	-$123K	0.11%	196
2021 Q3	$512K	Sell	4,289 -667	-13%	-$80.1K	0.12%	186
2021 Q2	$566K	Buy	4,956 +3,332	+205%	+$394K	0.13%	164
2021 Q1	$192K	Hold	1,624	–	–	0.05%	304
2020 Q4	$159K	Sell	1,624 -14,196	-90%	-$1.42M	0.05%	339
2020 Q3	$1.53M	Buy	15,820 +15,803	+92,959%	+$1.57M	0.44%	45
2020 Q2	$1.71K	Sell	17 -33,658	-100%	-$3.1M	﹤0.01%	515
2020 Q1	$2.98M	Buy	33,675 +33,563	+29,967%	+$2.96M	0.83%	26
2019 Q4	$10.2K	Sell	112 -45,757	-100%	-$3.92M	﹤0.01%	414
2019 Q3	$3.78M	Buy	45,869 +5,579	+14%	+$480K	0.68%	31
2019 Q2	$3.43M	Buy	40,290 +40,189	+39,791%	+$3.18M	0.6%	52
2019 Q1	$8.03K	Hold	101	–	–	﹤0.01%	401
2018 Q4	$7.51K	Hold	101	–	–	﹤0.01%	477
2018 Q3	$9.24K	Hold	101	–	–	﹤0.01%	443
2018 Q2	$8.65K	Sell	101 -53	-34%	-$4.66K	﹤0.01%	460
2018 Q1	$13.1K	Hold	154	–	–	﹤0.01%	410
2017 Q4	$14.1K	Sell	154 -17	-10%	-$1.41K	﹤0.01%	387
2017 Q3	$14.1K	Sell	171 -15	-8%	-$1.27K	﹤0.01%	375
2017 Q2	$17.6K	Hold	186	–	–	﹤0.01%	369
2017 Q1	$16.5K	Buy	+186	New	+$16.3K	﹤0.01%	336
2016 Q4	–	Sell	-201	Closed	-$16.2K	–	655
2016 Q3	$16.2K	Sell	201 -22	-10%	-$1.89K	﹤0.01%	377
2016 Q2	$17.7K	Sell	223 -12	-5%	-$962	﹤0.01%	339
2016 Q1	$20.3K	Buy	+235	New	+$20.9K	﹤0.01%	376
2015 Q4	–	Sell	-342	Closed	-$32.5K	–	536
2015 Q3	$32.5K	Sell	342 -5	-1%	-$525	﹤0.01%	298
2015 Q2	$36.9K	Sell	347 -29	-8%	-$3.27K	﹤0.01%	304
2015 Q1	$42.7K	Sell	376 -137,984	-100%	-$13.9M	﹤0.01%	325
2014 Q4	$12.5M	Buy	+138,360	New	+$11.9M	1.73%	29

Other funds holding COR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Exane Derivatives's COR Position: Q2 2022 in Review

Exane Derivatives reduced its Cencora (COR) stake by 99% in Q2 2022, selling an estimated $430K and leaving 24 shares worth $3.4K. The position accounts for ﹤0.01% of the portfolio, ranked #406.

Exane Derivatives first reported a position in COR in Q4 2014 and has held it in 29 quarters since. The position peaked at $12.5M in Q4 2014. 895 funds tracked by Wall St. Rank hold COR as of Q2 2022.

Exane Derivatives held 24 shares of Cencora worth $3.4K as of Q2 2022.
Exane Derivatives sold 2,810 Cencora shares in Q2 2022, an estimated $430K.
Cencora made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #406 holding.
Exane Derivatives first reported a position in Cencora in Q4 2014 and has held it in 29 quarters since.
Exane Derivatives's Cencora position peaked at $12.5M in Q4 2014.
895 funds tracked by Wall St. Rank held Cencora as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.